Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

20.46USD
22 Feb 2018
Change (% chg)

$-0.05 (-0.24%)
Prev Close
$20.51
Open
$20.74
Day's High
$20.96
Day's Low
$20.30
Volume
285,860
Avg. Vol
454,806
52-wk High
$23.50
52-wk Low
$5.47

Chart for

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $1,341.42
Shares Outstanding(Mil.): 93.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

05 Feb 2018

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

08 Jan 2018

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

02 Nov 2017

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

30 Oct 2017

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

10 Oct 2017

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

29 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.91 0.00
Pfizer Inc. (PFE.N) $35.74 -0.02
Novartis AG (NOVN.S) CHF79.98 -0.22
Merck & Co., Inc. (MRK.N) $54.57 +0.02
Roche Holding Ltd. (ROG.S) CHF223.30 -0.20
Roche Holding Ltd. (RO.S) CHF226.40 -1.20
Abbott Laboratories (ABT.N) $58.99 0.00
Bayer AG (BAYGn.DE) €98.44 +0.01
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.89 --

Earnings vs. Estimates